{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:57:16Z","timestamp":1791233836643,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"2022 Shanghai Top Priority Research Center Construction Program","award":["(2022ZZ01011)"],"award-info":[{"award-number":["(2022ZZ01011)"]}]},{"name":"2022 National Natural Science Fund","award":["(Youth Fund, No.82203138, YC)"],"award-info":[{"award-number":["(Youth Fund, No.82203138, YC)"]}]},{"name":"2021 Changhai Hospital Educational Sponsorship Fund","award":["(CHPY2021B24, General Program, YC)"],"award-info":[{"award-number":["(CHPY2021B24, General Program, YC)"]}]},{"name":"2021 Naval Medical University Basic Science Research Youth Start-up Fund","award":["(2021QN29, YC)"],"award-info":[{"award-number":["(2021QN29, YC)"]}]},{"name":"2024 Changzheng Hospital Investigator-initiated Clinical Research Program","award":["(incubation program, 2023YJBF-FH01, SR)"],"award-info":[{"award-number":["(incubation program, 2023YJBF-FH01, SR)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13201-w","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:23:42Z","timestamp":1745468622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["NEoAdjuvant radiohormonal therapy versus standard of care for oligometastatic prostate cancer (NEAR-TOP): study protocol of a multicenter, open-label, randomised controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhiguo","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duocai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shancheng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"13201_CR1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-249.","DOI":"10.3322\/caac.21660"},{"issue":"5","key":"13201_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584\u201390.","journal-title":"Chin Med J"},{"issue":"22","key":"13201_CR3","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1001\/jama.296.22.2683","volume":"296","author":"YN Wong","year":"2006","unstructured":"Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS, Wan F, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296(22):2683\u201393.","journal-title":"JAMA"},{"issue":"2","key":"13201_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpuro1296","volume":"6","author":"WP Harris","year":"2009","unstructured":"Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76\u201385.","journal-title":"Nat Clin Pract Urol"},{"issue":"3","key":"13201_CR5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.eururo.2012.05.047","volume":"62","author":"G Novara","year":"2012","unstructured":"Novara G, Ficarra V, Mocellin S, Ahlering TE, Carroll PR, Graefen M, et al. Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol. 2012;62(3):382\u2013404.","journal-title":"Eur Urol"},{"issue":"17","key":"13201_CR6","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1200\/JCO.2017.72.8030","volume":"35","author":"KS Virgo","year":"2017","unstructured":"Virgo KS, Basch E, Loblaw DA, Oliver TK, Rumble RB, Carducci MA, et al. Second-line hormonal therapy for men with Chemotherapy-Na\u00efve, castration-resistant prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncology: Official J Am Soc Clin Oncol. 2017;35(17):1952\u201364.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"3","key":"13201_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.eururo.2019.09.004","volume":"77","author":"NJ Sathianathen","year":"2020","unstructured":"Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G, et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate Cancer: a systematic review and network Meta-analysis. Eur Urol. 2020;77(3):365\u201372.","journal-title":"Eur Urol"},{"issue":"1","key":"13201_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR, Oligometastases. J Clin Oncology: Official J Am Soc Clin Oncol. 1995;13(1):8\u201310.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"1","key":"13201_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1200\/JOP.2016.018846","volume":"13","author":"PT Tran","year":"2017","unstructured":"Tran PT, Antonarakis ES. Altering the natural history of oligometastatic prostate Cancer with local therapies: reality Versus Illusion. J Oncol Pract. 2017;13(1):21\u20134.","journal-title":"J Oncol Pract"},{"issue":"1","key":"13201_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.eururo.2015.11.010","volume":"70","author":"CJD Wallis","year":"2016","unstructured":"Wallis CJD, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R, et al. Surgery Versus Radiotherapy for clinically-localized prostate Cancer: a systematic review and Meta-analysis. Eur Urol. 2016;70(1):21\u201330.","journal-title":"Eur Urol"},{"issue":"24","key":"13201_CR11","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.2016.67.4788","volume":"34","author":"CG Rusthoven","year":"2016","unstructured":"Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, et al. Improved survival with prostate Radiation in Addition to Androgen Deprivation Therapy for Men with newly diagnosed metastatic prostate Cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2016;34(24):2835\u201342.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"10162","key":"13201_CR12","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353\u201366.","journal-title":"Lancet"},{"issue":"3","key":"13201_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boeve","year":"2019","unstructured":"Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the prostate in patients with primary bone metastatic prostate Cancer in a prospective Randomised Clinical Trial: data from the HORRAD Trial. Eur Urol. 2019;75(3):410\u20138.","journal-title":"Eur Urol"},{"issue":"1","key":"13201_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","volume":"76","author":"S Burdett","year":"2019","unstructured":"Burdett S, Boeve LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate Cancer: a STOPCAP systematic review and Meta-analysis. Eur Urol. 2019;76(1):115\u201324.","journal-title":"Eur Urol"},{"issue":"29","key":"13201_CR15","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-term outcomes and genetic predictors of response to Metastasis-Directed Therapy Versus Observation in oligometastatic prostate Cancer: analysis of STOMP and ORIOLE trials. J Clin Oncology: Official J Am Soc Clin Oncol. 2022;40(29):3377\u201382.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"33","key":"13201_CR16","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.3748\/wjg.v25.i33.4850","volume":"25","author":"G Feeney","year":"2019","unstructured":"Feeney G, Sehgal R, Sheehan M, Hogan A, Regan M, Joyce M, et al. Neoadjuvant radiotherapy for rectal cancer management. World J Gastroenterol. 2019;25(33):4850\u201369.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"13201_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.radonc.2008.03.019","volume":"88","author":"S Supiot","year":"2008","unstructured":"Supiot S, Shubbar S, Fleshner N, Warde P, Hersey K, Wallace K, et al. A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol. 2008;88(1):53\u201360.","journal-title":"Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol"},{"issue":"4","key":"13201_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00345-018-2174-1","volume":"36","author":"A Basiri","year":"2018","unstructured":"Basiri A, de la Rosette JJ, Tabatabaei S, Woo HH, Laguna MP, Shemshaki H. Comparison of retropubic, laparoscopic and robotic radical prostatectomy: who is the winner? World J Urol. 2018;36(4):609\u201321.","journal-title":"World J Urol"},{"issue":"11","key":"13201_CR19","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1007\/s00464-013-3046-9","volume":"27","author":"AD Asimakopoulos","year":"2013","unstructured":"Asimakopoulos AD, Miano R, Di Lorenzo N, Spera E, Vespasiani G, Mugnier C. Laparoscopic versus robot-assisted bilateral nerve-sparing radical prostatectomy: comparison of pentafecta rates for a single surgeon. Surg Endosc. 2013;27(11):4297\u2013304.","journal-title":"Surg Endosc"},{"issue":"2","key":"13201_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11684-022-0939-9","volume":"17","author":"Y Chang","year":"2023","unstructured":"Chang Y, Zhao X, Xiao Y, Yan S, Xu W, Wang Y, et al. Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I\/II clinical trial. Front Med. 2023;17(2):231\u20139.","journal-title":"Front Med"},{"issue":"5","key":"13201_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686\u2013700.","journal-title":"Lancet Oncol"},{"issue":"5","key":"13201_CR22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","volume":"24","author":"G Attard","year":"2023","unstructured":"Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol. 2023;24(5):443\u201356.","journal-title":"Lancet Oncol"},{"key":"13201_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","volume":"84","author":"LHM Rydzewska","year":"2017","unstructured":"Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer. 2017;84:88\u2013101.","journal-title":"Eur J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13201-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13201-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13201-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:23:44Z","timestamp":1745468624000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13201-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13201"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13201-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4894517\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"11 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol, along with any amendments, informed consent, and the patient information brochure, underwent thorough review and received approval. Ethical approval for this study has been granted by the review committee (CHEC2022-226) and has been documented with the ethics committees of the participating centers. The study will be conducted in strict adherence to local laws and regulations, following the ethical principles outlined in the Declaration of Helsinki, and in accordance with the Good Clinical Practice (GCP) principles for clinical trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients and\/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}},{"value":"Potential participants will be notified by the urologist. Informed consent(Supplementary Material S1) will be obtained from all participants and co-signed by the clinician providing the patient information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"768"}}